Bone Care International Announces Patent Issuance
08 Juni 2005 - 12:42AM
PR Newswire (US)
Bone Care International Announces Patent Issuance Patent for
Stabilized Hydroxyvitamin D2 Products Covers Hectorol(R)
(doxercalciferol) MIDDLETON, Wis., June 7 /PRNewswire-FirstCall/ --
Bone Care International, Inc. (NASDAQ:BCII) announced today that
the U.S. Patent and Trademark Office has issued to it U.S. Patent
Number 6,903,083 entitled "Stabilized hydroxyvitamin D." The patent
claims a stabilized 1alpha-hydroxyvitamin D2 and pharmaceutical
products or compositions that include such an active component. The
stabilized hydroxyvitamin D2 products covered under this patent are
characterized by a purity profile defined by levels of impurities
and residual solvents. Hectorol(R), Bone Care's novel vitamin D
hormone therapy that treats secondary hyperparathyroidism in
patients with moderate to severe chronic kidney disease and
end-stage renal disease, is covered by this new composition of
matter patent that will expire in 2021. Mr. Paul Berns, President
and Chief Executive Officer, Bone Care International stated, "This
new patent on stabilized hydroxyvitamin D2 products expands the
Hectorol(R)-related patent portfolio and extends the protected time
horizon." Bone Care International (http://www.bonecare.com/) is a
specialty pharmaceutical company engaged in the discovery,
development and commercialization of innovative therapeutic
products to treat the unmet medical needs of patients with
debilitating conditions and life-threatening diseases. Our current
commercial and therapeutic focus is in nephrology, utilizing
Hectorol(R), a novel vitamin D hormone therapy, to treat secondary
hyperparathyroidism in patients with moderate to severe chronic
kidney disease and end-stage renal disease. In addition to chronic
kidney disease, the Company is developing vitamin D hormone
therapies to treat hyperproliferative disorders such as cancer and
psoriasis. Contact Bone Care International, Inc. Brian J. Hayden
Chief Financial officer 608-662-7800 This press release contains
forward-looking statements. Statements relating to future sales,
costs of sales, other expenses, profitability, financial resources,
or products and production schedules, or statements that predict or
indicate future events and trends and which do not relate solely to
historical matters identify forward-looking statements.
Forward-looking statements are made pursuant to the safe harbor
provisions of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934 and are based on
management's beliefs as well as assumptions made by and information
currently available to management. Accordingly, the Company's
actual results may differ materially from those expressed or
implied in such forward-looking statements due to known and unknown
risks and uncertainties that exist in the Company's operations and
business environment, including, among other factors, the ability
of the Company and each of its suppliers of doxercalciferol,
Hectorol(R) Injection and Hectorol(R) Capsules to meet the
Company's anticipated production schedules, technical risks
associated with the development of new products, regulatory
policies in the United States and other countries, risks associated
with our ability to avoid or minimize delays in/or interruption of
the manufacture and supply of our products, including the approvals
of regulatory authorities in connection therewith, reimbursement
policies of public and private health care payors, introduction and
acceptance of new drug therapies, competition from existing
products and from new products or technologies, the failure by the
Company to produce anticipated cost savings or improve
productivity, the timing and magnitude of capital expenditures and
acquisitions, currency exchange risks, economic and market
conditions in the United States, Europe and the rest of the world,
and other risks associated with the Company's operations. The
Company disclaims any obligation to update any such factors or to
publicly announce any revisions to any of the forward-looking
statements contained herein to reflect future events or
developments. DATASOURCE: Bone Care International, Inc. CONTACT:
Brian J. Hayden, Chief Financial officer of Bone Care
International, Inc., 608-662-7800 Web site:
http://www.bonecare.com/
Copyright
BCII Enterprises (PK) (USOTC:BCII)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
BCII Enterprises (PK) (USOTC:BCII)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
Echtzeit-Nachrichten über BCII Enterprises Inc (PK) (OTCMarkets): 0 Nachrichtenartikel
Weitere Bone Care International - Common Stock (MM) News-Artikel